SUMMARY OF CONCLUSIONS FROM A CONSENSUS PANEL OF EXPERTS ON THE IMPORTANCE OF RIVAROXABAN IN THE MANAGEMENT OF PATIENTS RECOVERING FROM ACUTE CORONARY SYNDROME
https://doi.org/10.21518/2307-1109-2015-2-86-94
Abstract
Despite the widespread introduction of primary percutaneous coronary interventions (PCI) and the use of new powerful antiplatelet drugs for the management of patients with acute coronary syndrome (ACS) at high risk, the relapse rate of coronary events associated with atherothrombosis remains sufficiently high. In the CURE [1] study the prevalence of myocardial infarction (MI), cere-brovascular accident (CVA) and cardiovascular death (CVD) among patients with ACS without ST elevation, who received aspirin and clopidogrel within 12 months, was 9.3%, and in the PLATO [2] study the frequency of above complications in a group of high-risk patients with ACS, who received a new P2Y12 inhibitor tikagrelor, amounted to 9.8%.
About the Authors
M. Ya. Ruda
Myasnikov Cardiology Institute RK NPK of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
A. I. Syrkin
Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
E. P. Panchenko
Myasnikov Cardiology Institute RK NPK of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
I. S. Yavelov
Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
O. V. Averkov
Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation
Russian Federation
Russian Federation
R. M. Shahnovich
Filatov City Clinical Hospital No. 15 of the Moscow Health Department, Department of Internal Medicine FPK MR RUDN
Russian Federation
Russian Federation
A. L. Komarov
Институт кардиологии им. А.Л. Мясникова ФГБУ РКНПК МЗ РФ
Russian Federation
Russian Federation
References
1. Yusuf S et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndroms without ST segment elevation. NEnglJMed, 2001. 345(7): 494-502.
2. Wallentine L et al. Ticagrelor versus clopidogrel in patients with acure coronary syndromes. NEnglJ Med, 2009. 361(11): 1045-1057.
3. Stone GW et al. A prospective Natural-History Study of Coronary atherosclerosis. NEnglJMed, 2011.364:226-235.
4. Merlini et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation, 1994. 90(1): 61-68.
5. Husted SE et al. Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularization. Eur heartJ, 2002. 23(15): 1213-1218.
6. Rothberg MB et al. Warfarin plus aspirin after MI or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med, 2005. 143(4): 241-250.
7. Hansen ML et al. Risk of bleeding with single, dual, or triple therapy witn warfarin, aspirin, and clopidogrel inpatients with atrial fibrillation. Arch Intern Med, 2010.(16): 1433-1441.
8. Mega J et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI46): a randomized, double-blined, phase II trial. Lancet, 2009. 374: 29-38.
9. Mega J et al. Rivaroxaban in patients with a recent acute coronary syndrome. NEnglJMed, 2012. 366: 9-11.
10. Mega J et al. Comparison of the efficacy and safety of two Rivaroxaban doses in acute coronary syndrome (from ATLAS ACS-TIMI 5 1).AmJ Cardiol, 2013. 112: 472-478.
11. Mega J et al. Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction.JAm Coll Cardiol, 2013. 61: 1853-9.
12. Gibson M et al. Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. J Am Coll Cardiol, 2013. 62: 286-290.
13. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J, 2012. 33: 2569-2619.
14. 2014 ESC/EACTS Guidelines on myocardial revascularization. doi: 10.1093eurheartj/ehu278.
15. 2015 ESC Guigelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. doi:10.1093/eur-heartj/ehv320.
Review
For citations:
Ruda M.Ya., Syrkin A.I., Panchenko E.P., Yavelov I.S., Averkov O.V., Shahnovich R.M., Komarov A.L. SUMMARY OF CONCLUSIONS FROM A CONSENSUS PANEL OF EXPERTS ON THE IMPORTANCE OF RIVAROXABAN IN THE MANAGEMENT OF PATIENTS RECOVERING FROM ACUTE CORONARY SYNDROME. Aterotromboz = Atherothrombosis. 2015;(2):86-94. (In Russ.) https://doi.org/10.21518/2307-1109-2015-2-86-94
Views:
1041
This work is licensed under a Creative Commons Attribution Attribution-NonCommercial-NoDerivs License.
Email this article 